Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation

European Journal of Haematology

Volumn 79, Issue 1, 2007, Pages 17-24

  Mori, Yasuo ^a   Yoshimoto, Goichi ^a   Kumano, Takashi ^a   Miyamoto, Toshihiro ^b   Iino, Tadafumi ^b   Takenaka, Katsuto ^a   Iwasaki, Hiromi ^b   Harada, Naoki ^a   Kinukawa, Naoko ^b   Nagafuji, Koji ^a   Teshima, Takanori ^b   Shimoda, Kazuya ^a   Akashi, Koichi ^b   Harada, Mine ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Acute myelogenous leukaemia; CD34; FLT3 internal tandem duplication; Myelomonocytic markers; Nucleophosmin mutation

Indexed keywords

CD11B ANTIGEN; CD135 ANTIGEN; CD14 ANTIGEN; CD34 ANTIGEN; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; BLOOD CELL COUNT; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENDER; GENE DUPLICATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL;

ADULT; AGED; ANTIGENS, CD34; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; MONOCYTES; MUTATION; NUCLEAR PROTEINS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34347255760     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00866.x     Document Type: Article

References (27)

1. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998 92 : 2322 33.
2. Roumier C, Fenaux P, Lafage M, Imbert M, Eclache V, Preudhomme C. New mechanisms of AML1 gene alteration in hematological malignancies. Leukemia 2003 17 : 9 16.
3. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen DG. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001 27 : 263 70.
4. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002 99 : 4326 35.
5. Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 2004 89 : 920 5.
6. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005 352 : 254 66.
7. Baldus CD, Tanner SM, Ruppert AS, et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 2003 102 : 1613 8.
8. Marcucci G, Baldus CD, Ruppert AS, et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 2005 23 : 9234 42.
9. Turner AM, Lin NL, Issarachai S, Lyman SD, Broudy VC. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood 1996 88 : 3383 90.
10. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997 11 : 1605 9.
11. Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, Dohner H, Dohner K. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002 100 : 4372 80.
12. Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H, Naoe T. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998 12 : 1333 7.
13. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999 93 : 3074 80.
14. Yoshimoto G, Nagafuji K, Miyamoto T, et al. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2005 36 : 977 83.
15. Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005 106 : 3747 54.
16. Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A, Bullinger L, Frohling S, Dohner H. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005 106 : 3740 6.
17. Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005 106 : 2854 61.
18. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006 107 : 4011 20.
19. Sipos K, Olson MO. Nucleolin promotes secondary structure in ribosomal RNA. Biochem Biophys Res Commun 1991 177 : 673 8.
20. Tarapore P, Okuda M, Fukasawa K. A mammalian in vitro centriole duplication system: evidence for involvement of CDK2/cyclin E and nucleophosmin/B23 in centrosome duplication. Cell Cycle 2002 1 : 75 81.
21. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, Haferlach T, Hiddemann W, Falini B. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005 106 : 3733 9.
22. Eto T, Akashi K, Harada M, Shibuya T, Takamatsu Y, Teshima T, Niho Y. Biological characteristics of CD7 positive acute myelogenous leukaemia. Br J Haematol 1992 82 : 508 14.
23. Miwa H, Mizutani M, Mahmud N, et al. Biphasic expression of CD4 in acute myelocytic leukemia (AML) cells: AML of monocyte origin and hematopoietic precursor cell origin. Leukemia 1998 12 : 44 51.
24. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007 109 : 431 48.
25. Haferlach T, Bacher U, Haferlach C, Kern W, Schnittger S. Insight into the molecular pathogenesis of myeloid malignancies. Curr Opin Hematol 2007 14 : 90 97.
26. Munoz L, Aventin A, Villamor N, Junca J, Acebedo G, Domingo A, Rozman M, Torres JP, Tormo M, Nomdedeu JF. Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication. Haematologica 2003 88 : 637 45.
27. Levis M, Murphy KM, Pham R, Kim KT, Stine A, Li L, McNiece I, Smith BD, Small D. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood 2005 106 : 673 80.